Justin Taylor, MD

About Me

I am a medical oncologist who specializes in treating leukemia and myelodysplastic syndromes. I have a strong interest in caring for people who have rare forms of these diseases. I also have expertise in early-phase clinical trials of targeted therapies for these illnesses. I help my patients participate in these research studies when they are eligible.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

I decided to pursue a career in oncology because I saw the need to develop better-tolerated and more-effective treatments for people with cancer. That’s why I am also a scientist investigating how normal cells become cancerous and how we can target that process with precision therapies.

My research focuses on finding mutations that occur in chronic lymphocytic leukemia and hairy cell leukemia. My goal is to develop new treatments for these diseases. I am also working on a trial to test a drug that would treat specific types of mutations, called splicing factor mutations. They are present in people with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML). Our research helped lead to FDA approval of a breakthrough new treatment, called enasidenib (Idhifa®), for AML that has stopped responding to other therapies. We found that people who received this drug had higher response rates and lived longer than people who received existing treatments.

When I meet with patients, it’s my goal that they leave their visit feeling more knowledgeable about and comfortable with their treatment plan than when they walked through the door. We’ll spend as much time together as needed to make sure this happens.

  • Clinical Expertise: Chronic Lymphocytic Leukemia (CLL); Hairy Cell Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
  • Awards and Honors: American Society of Clinical Oncology Young Investigator Award (2017); American Society of Hematology Medical Faculty Development Program (2017); Hairy Cell Leukemia Foundation Fellowship Program (2017)
  • Languages Spoken: English
  • Education: MD, University of New Mexico
  • Residencies: Internal Medicine - Brigham and Women’s Hospital of Harvard Medical School
  • Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Internal Medicine; Medical Oncology

See My Colleagues

Publications

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. The Journal of clinical investigation. 2018; 128(9):3819-3825. PubMed [journal] PMID: 29920189 PMCID: PMC6118587

Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer cell. 2018; 34(2):225-241.e8. PubMed [journal] PMID: 30107174

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2018; PubMed [journal] PMID: 30038380

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018; 559(7712):125-129. NIHMSID: NIHMS964938 PubMed [journal] PMID: 29950729 PMCID: PMC6121718

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature medicine. 2018; 24(4):497-504. PubMed [journal] PMID: 29457796

Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017 Jul 27;130(4):410-423. PubMed PMID: 28600336; PubMed Central PMCID: PMC5533199.

Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 Jun;22(6):672-8. PubMed PMID: 27135740; PubMed Central PMCID: PMC4899191.

Taylor J, Kim SS, Stevenson KE, Nori A, Kopp N, Louissaint A, Harris N, Hochberg EP, Chen Y, Lovitch SB, DeAngelo DJ, Wadleigh M, Steensma DP, Motyckova G, Stone RM, Neuberg DS, Jardin F, Piccaluga P, Weinstock DM, Lane AA. Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. Blood. 122(21).

Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Aug 11;PubMed PMID: 28801450.

Taylor J, Abdel-Wahab O. Hematology. 7th ed. Hoffman R, editor. Philadelphia: Elsevier; Chapter 10, Stem Cell Model of Hematologic Diseases2408p.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more Arrow rightAn icon showing an arrow pointing to the right.

Insurance

Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.